Ascletis Pharma has reported positive topline outcomes from its US Phase Ia single ascending dose (SAD) study of the oral ...

The trial will enrol nearly 280 adult subjects with obesity. Credit: Hunterframe / Shutterstock. Viking Therapeutics has announced the start of a Phase II clinical trial for VK2735, an oral tablet ...

"Obesity is a global epidemic with multifaceted ... inflammatory effects in a solid dosage form that can be taken as a tablet or capsule. Senior researcher, Dr. Paul Joyce says that combining ...

LONDON, Dec 23 (Reuters) - Eli Lilly's (LLY.N), opens new tab obesity drug Mounjaro will be available through Britain's state health system for some patients from March, after the drugs cost ...

Millions of people are being “overdiagnosed” as overweight or obese as scientists say there are problems with the main BMI measure. Body mass index has long been used to categorise people but ...

Scheduled for 13 weeks, the trial will assess the therapy’s safety, tolerability, and efficacy in weight loss.

Compared with poor response, good response to obesity treatment was associated with lower risk of type 2 diabetes (adjusted ...

Jan 8 (Reuters) - Eli Lilly's (LLY.N), opens new tab obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, broadening access to the ...

pharmacokinetics and weight loss efficacy of VK2735 dosed as an oral tablet once daily for 13 weeks. The trial will enroll approximately 280 adults who are obese (BMI ≥30 kg/m 2), or adults who ...